Jia Lei
Beijing, Beijing Municipality, 0086, China
Location status: Recruiting
NCT Number: NCT05437965
This project aims to establish a clinical cohort and diagnostic assessment framework by conducting a national multicenter cohort registry study. Through the collection of patients' clinical characteristics, it will achieve the registration, management, follow-up, and analysis of patients with Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR).
Interested in participating?
Request Info18 year and older
All sexes
Observational
Beijing, Beijing Municipality, 0086, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment made by experienced clinicians
Time frame: 10 year
Time to the incidence of target vessel failure, a composite of cardiovascular death, target vessel-related myocardial infarction, and target vessel-related revascularization.
Contact information is provided by the study sponsor or research team.
China National Center for Cardiovascular Diseases
Other Gov
Acronym: RECUR Registry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05618353
Arterial Occlusive Diseases, Arteriosclerosis
Birmingham, Alabama, United States
View Trial DetailsNCT06579807
Arterial Occlusive Diseases, Arteriosclerosis
Rio de Janeiro, Brazil
View Trial DetailsNCT07476703
AORTIC VALVE DISEASES, Aneurysm
Stockholm, Sweden
View Trial DetailsNCT06572267
Arterial Occlusive Diseases, Arteriosclerosis
Xi'an, Shannxi, China
View Trial Details